San Francisco AIDS Foundation news story
“Breakthrough” HIV infections among people receiving long-acting injectable lenacapavir for PrEP in two major clinical trials were a topic of discussion at CROI 2026.
Across two large clinical trials testing long-acting lenacapavir for PrEP, with thousands of cisgender women, men who have sex with men, and gender diverse people who have sex with men, a total of four individuals seroconverted during the study period while receiving on-time medication injections.
Why did lenacapavir fail to protect a small number of people from acquiring HIV in the study?, questioned one clinician from the University of Colorado during the presentation’s Q&A. “I think patients want to know, and I think we need that information soon. I’ve already had someone who declined to use lenacapavir because of the breakthrough infections.”
Read the full news story here.
Source : San Francisco AIDS Foundation